Patents by Inventor Douglas P. Cerretti

Douglas P. Cerretti has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Patent number: 5962647
    Abstract: Cloning and expression of nucleotide DNA segments encoding bovine IL-1.beta., and processes for producing purified bovine IL-1.beta. as a product of recombinant cell culture, are disclosed.
    Type: Grant
    Filed: January 29, 1992
    Date of Patent: October 5, 1999
    Assignee: Immunex Corporation
    Inventors: Douglas P. Cerretti, Brian S. Davis, Charles R. Maliszewski
  • Patent number: 5919905
    Abstract: The invention is directed to LERK-6 as a purified and isolated protein, the DNA encoding the LERK-6, host cells transfected with cDNAs encoding LERK-6.
    Type: Grant
    Filed: August 29, 1997
    Date of Patent: July 6, 1999
    Assignee: Immunex Corporation
    Inventor: Douglas P. Cerretti
  • Patent number: 5830742
    Abstract: A metalloprotease that converts TNF-.alpha. from the 26 kD cell form to the 17 kD form has been isolated and purified and the cDNA sequence known. In particular, the protease has a molecular weight of approximately 80 kD. The isolated and purified protease is useful for designing an inhibitor thereof, and may find use as a therapeutic agent. Assays for detecting the protease-inhibiting activity of a molecule are also an aspect of the invention.
    Type: Grant
    Filed: May 23, 1996
    Date of Patent: November 3, 1998
    Assignee: Immunex Corporation
    Inventors: Roy A. Black, Charles Rauch, Carl J. March, Douglas P. Cerretti
  • Patent number: 5738844
    Abstract: Hek ligand (hek-L) polypeptides as well as DNA sequences, vectors and transformed host cells useful in providing hek-L polypeptides. The hek-L polypeptides bind to a cell surface receptor (hek) that is a member of the receptor tyrosine kinase family. Hek is expressed on cells that include certain tumor cell lines. The hek-L polypeptides also bind a distinct receptor tyrosine kinase known elk.
    Type: Grant
    Filed: May 30, 1995
    Date of Patent: April 14, 1998
    Assignee: Immunex Corporation
    Inventors: M. Patricia Beckmann, Douglas P. Cerretti
  • Patent number: 5516658
    Abstract: Hek ligand (hek-L) polypeptides as well as DNA sequences, vectors and transformed host cells useful in providing hek-L polypeptides. The hek-L polypeptides bind to a cell surface receptor (hek) that is a member of the receptor tyrosine kinase family. Hek is expressed on cells that include certain tumor cell lines. The hek-L polypeptides also bind a distinct receptor tyrosine kinase known elk.
    Type: Grant
    Filed: May 9, 1994
    Date of Patent: May 14, 1996
    Assignee: Immunex Corporation
    Inventors: M. Patricia Beckmann, Douglas P. Cerretti
  • Patent number: 5317087
    Abstract: Interleukin-2 receptor derived from normal and malignant cells has been purified by use of various techniques including affinity chromatography in conjunction with a monoclonal antibody directed to the receptor. The purification process also includes reversed phased high performance liquid chromatography. By these techniques, interleukin-2 receptor has been purified to homogeneity. The high purification of the interleukin-2 receptor has made possible the sequencing of the amino acid residues at the N-terminal of this protein molecule. Double-stranded cDNA is prepared from polyadenylated RNA extracted from cell lines or other sources known to produce IL-2 receptor. The cDNA is inserted within a plasmid vector and then the recombinant plasmid employed to transform an appropriate host. Transformed hosts are identified and grouped into pools.
    Type: Grant
    Filed: October 22, 1990
    Date of Patent: May 31, 1994
    Assignee: Immunex Corporation
    Inventors: Douglas P. Cerretti, Cosman, Steven K. Dower, Carl J. March, David L. Urdal, Alf D. Larsen
  • Patent number: 5266311
    Abstract: Cloning and expression of DNA segments encoding bovine IL-1.alpha., and processes for producing purified bovine IL-1.alpha. as a product of recombinant cell culture, are disclosed.
    Type: Grant
    Filed: December 23, 1991
    Date of Patent: November 30, 1993
    Assignee: Immunex Corporation
    Inventors: Douglas P. Cerretti, Charles R. Maliszewski, Michael Schoenborn
  • Patent number: 5171675
    Abstract: A macrophage colony stimulating factor, M-CSF.gamma., which is a primary translation product of an alternative mRNA splicing event and is a precursor to biologically active M-CSF. DNA sequences encoding M-CSF.gamma. and recombinant expression vectors comprising the DNA sequences.
    Type: Grant
    Filed: August 8, 1989
    Date of Patent: December 15, 1992
    Inventors: Douglas P. Cerretti, Dirk M. Anderson, Robert J. Tushinski, Byron M. Gallis, David Cosman
  • Patent number: 5122459
    Abstract: Double-stranded cDNA is prepared from polyadenylated RNA extracted from activated human peripheral blood adherent mononuclear cells. The cDNA is inserted within a plasmid vector and then the recombinant plasmid employed to transform an appropriate host. Transformed hosts are identified and grouped into pools. Plasmid DNA prepared from these pools is hybridized with a labeled, synthetic oligonucleotide probe corresponding to a portion of the amino acid sequence of the interleukin 1 protein. Pools of host cells that provide a positive signal to the probe are identified, plated out and then employed in direct bacterial colony hybridization with the same probe, thereby to isolate the particular positive colony. Plasmid DNA is prepared from this colony and characterized by restriction enzyme mapping and sequencing by chain-termination method. The coding region for the IL-1 gene is inserted into a shuttle vector for amplification of the vector followed by expression of functional IL-1.
    Type: Grant
    Filed: November 30, 1989
    Date of Patent: June 16, 1992
    Assignee: Immunex Corporation
    Inventors: Paul J. Conlon, III, David j. Cosman, Kenneth H. Grabstein, Thomas P. Hopp, Shirley R. Kronheim, Alf D. Larsen, Carl J. March, Virginia L. Price, Douglas P. Cerretti
  • Patent number: 5108911
    Abstract: A process for preparing bovine interleukin I.beta. (bIL-1.beta.) by culturing a microbial host transformed by a vector containing a DNA sequence encoding bIL-1.beta. under conditions suitable for the expression of bIL-1.beta. and recovering bIL-1.beta..
    Type: Grant
    Filed: August 11, 1989
    Date of Patent: April 28, 1992
    Assignee: Immunex Corporation
    Inventors: Douglas P. Cerretti, Brian S. Davis, Charles R. Maliszewski
  • Patent number: 5106733
    Abstract: Cloning and expression of DNA segments encoding bovine GM-CSF, and processes for producing recombinant bovine GM-CSF as a product of recombinant cell culture, are disclosed.
    Type: Grant
    Filed: May 22, 1989
    Date of Patent: April 21, 1992
    Assignee: Immunex Corporation
    Inventors: Paul E. Baker, Douglas P. Cerretti, William R. Clevenger, David J. Cosman, Charles R. Maliszewski
  • Patent number: 5006465
    Abstract: A process for preparing bovine interleukin-2 (bIL-2) by culturing a microbial host transformed by a vector containing a DNA sequence encoding bIL-2 under conditions suitable for the expression of bIL-2 and recovering bIL-2.
    Type: Grant
    Filed: August 11, 1989
    Date of Patent: April 9, 1991
    Inventors: Dirk M. Anderson, Paul E. Baker, Michael A. Cantrell, Douglas P. Cerretti, David J. Cosman, Steven D. Gimpel, Kenneth H. Grabstein, Alf D. Larsen, Kate N. McKereghan
  • Patent number: 4894333
    Abstract: Cloning and expression of DNA segments encoding bovine IL-.alpha., and processes for producing purified bovine IL-1.alpha. as a product of recombinant cell culture, are disclosed.
    Type: Grant
    Filed: May 28, 1987
    Date of Patent: January 16, 1990
    Assignee: Immunex Corporation
    Inventors: Douglas P. Cerretti, Charles R. Maliszewski, Michael A. Schoenborn
  • Patent number: 4882282
    Abstract: A chemically-synthesized oligonucleotide composing a portion of the nucleotide sequence of the human IL-2 is employed as a probe to isolate the gene coding for human IL-2. The human IL-2 gene is selected from a cDNA library prepared from RNA produced by mitogen-stimulated Jurkat cells. Double-stranded cDNA is prepared from polyadenylated RNA extracted from bovine cells thought to produce interleukin-2. Such cDNA is inserted within a plasmid vector and the recombinant plasmid employed to transform hosts. Plasmid DNA, prepared from pools of the transformed hosts, is hybridized with a probe composed of a large portion of the coding sequence of the human IL-2 gene. Pools of host cells that provide signal to the human cDNA probe are identified, subdivided, and rescreened until a single positive colony is identified. Bovine plasmid cDNA is prepared from this colony, and the bIL-2 gene is sequenced.
    Type: Grant
    Filed: July 31, 1986
    Date of Patent: November 21, 1989
    Assignee: Immunex Corporation
    Inventors: Dirk M. Anderson, Paul E. Baker, Michael A. Cantrell, Douglas P. Cerretti, David J. Cosman, Steven D. Gimpel, Kenneth H. Grabstein, Alf D. Larsen, Kate N. McKereghan
  • Patent number: 4879374
    Abstract: Cloning and expression of nucleotide DNA segments encoding bovine IL-1.beta., and processes for producing purified bovine IL-1.beta. as a product of recombinant cell culture, are disclosed.
    Type: Grant
    Filed: March 13, 1987
    Date of Patent: November 7, 1989
    Assignee: Immunex Corporation
    Inventors: Douglas P. Cerretti, Brian S. Davis, Charles R. Maliszewski